I think RNYLX is still ahead, they completed their utility study back in June. PIQ still waiting to release theirs.
But as it's been mentioned before, KidneyIntelX and PromarkerD are two different tests for different stages. Any progress RNYLX makes will bode well for PromarkerD, I think the biggest hurdle for both companies is getting health care professionals onboard in using these new predictive tool with their patients as part of standard of care. Getting the right key opinion leaders, conferences, peer reviewed studies are all part of that effort. It takes years for this stuff to make its way down to practitioners.
Patiently watching the SP, hoping for a good floor to accumulate more
PIQ Price at posting:
96.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)